PMV Pharmaceuticals is a precision oncology company that discovers and develops small molecule therapies targeting p53 mutations, which occur in approximately half of all human cancers. The company's lead candidate, rezatapopt, is an orally available drug designed to structurally correct misfolded p53 proteins and restore their tumor-suppressing function, with particular focus on the Y220C mutation found across multiple cancer types including ovarian, breast, and lung cancers. PMV generates revenue through licensing agreements and partnerships while advancing its clinical pipeline and pursuing regulatory approval, with plans to commercialize through a focused sales organization targeting oncology specialists upon FDA approval.